We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GEV:NYSEGE Vernova Inc. Analysis

Data as of 2026-05-21 - not real-time

$1,024.52

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

GE Vernova (GEV) is trading in a bullish technical environment with the short‑term moving averages stacked in order (20‑day above 50‑day above 200‑day) and the overall trend flagged as bullish. The RSI sits near the midpoint, suggesting limited momentum, while the MACD histogram is negative and the signal line is bearish, hinting at a short‑term pullback.
Fundamentally, the company delivers strong top‑line growth and an exceptional ROE, supported by a high‑margin electrification business and a strategic 2.5 GW nuclear‑gas plant partnership in Texas that aligns with rising AI‑driven data‑center power demand. However, the DCF fair‑value estimate lies well below the current market price, the forward PE is elevated, and trading volume is on a downtrend, raising concerns about valuation and liquidity. The dividend is modest with a very low payout ratio, making it sustainable despite the sizable debt load.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram signaling near‑term downside
  • Current price above DCF‑derived fair value
  • Decreasing volume trend reducing short‑term liquidity

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Robust revenue growth and high ROE indicating strong earnings trajectory
  • Analyst upgrades and positive sentiment around AI‑driven power demand
  • Strategic 2.5 GW nuclear‑gas plant partnership expanding the Power segment

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Diversified global footprint mitigating geographic concentration risk
  • Sustainable dividend supported by low payout ratio and strong cash flow
  • Elevated beta and sector volatility suggesting continued price swings

Key Metrics & Analysis

Financial Health

Revenue Growth16.30%
Profit Margin23.81%
P/E Ratio29.9
ROE75.71%
ROA2.38%
Debt/Equity24.93
P/B Ratio19.8
Op. Cash Flow$9.0B
Free Cash Flow$9.3B
Industry P/E29.5

Technical Analysis

TrendBullish
RSI48.4
Support$980.14
Resistance$1,181.95
MA 20$1,074.36
MA 50$978.28
MA 200$737.17
MACDBearish
VolumeDecreasing
Fear & Greed Index90.29

Valuation

Fair Value$894.44
Target Price$1,217.17
Upside/Downside18.80%
GradeOvervalued
TypeGrowth
Dividend Yield0.20%

Risk Assessment

Beta1.87
Volatility52.91%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.